Product Launches, Clinical Study Results, Historical Trials, Joint Lawsuits and Milestone Patient Enrollment - Research Report on Teva, Pacira, Novo Nordisk, Forest, and Amarin

NEW YORK, September 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), Novo Nordisk A/S (NYSE: NVO), Forest Laboratories, Inc. (NYSE: FRX), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Teva Pharmaceutical Industries Ltd Research Report

On September 24, 2013, Teva Pharmaceutical Industries Ltd (Teva) announced the launch of the generic equivalent to ADENOSCAN (adenosine injection) in the US. ADENOSCAN, marketed by Astellas Pharma, is supplied as 20mL and 30mL vials and is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The Company noted that it was first to file, making the product eligible for 180 days of marketing exclusivity. The Full Research Report on Teva Pharmaceutical Industries Ltd - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

Pacira Pharmaceuticals, Inc. Research Report

On September 19, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced results from a 200-patient study that evaluated the benefits of EXPAREL (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain management regimen in patients undergoing total knee arthroplasty (TKA), more commonly known as total knee replacement. Results of the study showed that patients treated with EXPAREL experienced better pain control with improved knee flexion and a shorter length of hospital stay compared to patients who received a femoral nerve block with a local anesthetic, which is the current standard of pain management for TKA. Further, results also revealed that the use of EXPAREL resulted in a substantial cost savings. The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c0aa_PCRX]

Novo Nordisk A/S Research Report

On September 25, 2013, Novo Nordisk A/S (Novo Nordisk) announced that recruitment for the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial assessing cardiovascular (CV) outcomes of Victoza, the once-daily GLP-1 analogue, resulted in a high-risk population with patient number exceeding the original target. The Company noted that the LEADER trial is the largest and longest clinical trial in Novo Nordisk's history, with data from more than 17,000 patient years of exposure collected to date. "Victoza® has a strong body of clinical evidence demonstrating its efficacy, both pre- and post-approval," said Dr. Steven P. Marso, Lead Investigator of the LEADER trial, and Professor of Medicine at Mid America Heart Institute at Saint Luke's Health System in Kansas City, Missouri. The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fee1_NVO]

Forest Laboratories, Inc. Research Report

On September 24, 2013, Forest Laboratories, Inc. and Forest Laboratories Holdings, Ltd (collectively known as Forest) announced that Royalty Pharma Collection Trust (Royalty Pharma) and Forest have jointly filed lawsuits in the US District Court for the District of Delaware against several companies for infringement of US Patent No. 6,602,911 ('911 patent), US Patent No. 7,888,342 ('342 patent), and US Patent No. 7,994,220 ('220 patent), relating to Forest's SAVELLA product. The Company licenses these patents from Royalty Pharma, and informed that the '911 patent, the '342 patent and the '220 patent expires in January 2023, November 2021, and September 2029, respectively. Forest and Royalty Pharma informed that they have received notification from the defendants named in the lawsuits, including Apotex Corp., Hetero USA Inc., Lupin Ltd., Mylan Pharmaceuticals, Inc., Par Pharmaceuticals, Inc., Ranbaxy Laboratories Ltd, and related companies and subsidiaries, stating that they have filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic version of SAVELLA before the expiration of these patents. The Full Research Report on Forest Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ea24_FRX]

Amarin Corporation plc Research Report

On September 25, 2013, Amarin Corporation plc (Amarin) announced that the number of patients enrolled in its REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study of Vascepa capsules has surpassed 6,000. "Reaching the 6,000 patient mark in the REDUCE-IT trial represents significant progress toward full enrollment and another significant highlight for Amarin in 2013," said Joseph Zakrzewski, Chairman and CEO of Amarin. "The results of REDUCE-IT may enable us to seek additional indications for Vascepa including cardiovascular risk reduction, which would represent a patient population estimated to be almost twice that of the combined indications studied in the MARINE and ANCHOR trials or approximately 70 million adults in the United States alone." The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner